OOIR: Observatory of International Research

Papers

(The H4-Index of European Heart Journal-Cardiovascular Pharmacotherapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	69
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	64
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	56
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	56
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	48
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	42
Early initiation of SGLT2 inhibitors after acute myocardial infarction	38
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? . Why can't we see the evidence?	35
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	34
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	33
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	31
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	31
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	30
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	29
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	28
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	27
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	27
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle	27
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	26
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	24
All about clinical trials	23
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	23
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	22
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	22
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	22